AVOQUIN 4% CREAM 50G

Indications

Approved Uses

Gradual bleaching of hyperpigmented skin conditions such as chloasma/melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation (e.g., post-inflammatory hyperpigmentation) as directed by a prescriber.

Off-Label Uses

Post-inflammatory hyperpigmentation (commonly used); other off-label uses include selected cases of drug-induced hyperpigmentation and acanthosis nigricans (limited evidence).

Dosage & Administration

Dosing by Condition

Hyperpigmentation (e.g., melasma/chloasma, freckles, lentigines, post-inflammatory hyperpigmentation): apply a thin layer to affected areas twice daily (morning and evening) as prescribed; reassess if no response by ~2 months and avoid prolonged continuous use without medical review.

Initial Dose

Apply thin layer to affected hyperpigmented area twice daily

Maintenance Dose

After achieving desired depigmentation, application may be reduced to maintain the effect, often twice weekly.

Maximum Dose

Apply a thin film to affected areas twice daily (morning and evening) only; do not exceed twice-daily application or apply to large body areas

Children's Dosage

Not approved for children under 12 years

Dose Adjustment Notes

No systemic dose adjustment is needed; if significant irritation occurs, reduce frequency (e.g., once daily or every other day) or temporarily stop; discontinue if no improvement after about 2 months of consistent use.

How to Take

Cleanse and dry the skin; apply a thin layer to hyperpigmented areas only (avoid normal surrounding skin) and rub in gently, typically twice daily (morning and evening) as prescribed; wash hands after application; avoid contact with eyes, mouth, and mucous membranes; use broad-spectrum sunscreen and minimize sun exposure during daytime.

Side Effects

Common Side Effects

Application-site irritation (burning/stinging), erythema/redness, dryness/peeling, pruritus; possible allergic contact dermatitis.

Side Effect Frequency

Common: local irritation (burning/stinging), erythema, dryness, pruritus; Uncommon/Rare: allergic contact dermatitis, blistering/skin cracking; Rare but serious with prolonged/inappropriate use: exogenous ochronosis and paradoxical hyperpigmentation.

Safety & Warnings

Contraindications

Hypersensitivity to hydroquinone or any component; do not use on sunburned, windburned, dry, chapped, or irritated/broken skin

Warnings & Precautions

Avoid eyes/mucous membranes and broken/irritated or sunburned skin; perform a patch test; use daily broad-spectrum sunscreen and protective measures; limit duration and area of use; discontinue if no response by ~2 months or if ochronosis/marked irritation occurs

Age Restriction

Not recommended for children <12 years unless directed and supervised by a physician

Driving Warning

Safe

Drug Interactions

Drug Interactions

Avoid concurrent use with benzoyl peroxide, hydrogen peroxide, or other peroxide products (temporary staining); use caution with other topical irritants/keratolytics (e.g., retinoids, AHA/BHA) due to additive irritation

Interaction Severity

MINOR: Concurrent use with other topical irritants/peeling agents (e.g., retinoids, AHAs, benzoyl peroxide) may increase irritation; MINOR: hydrogen peroxide may cause temporary staining/darkening at the application site.

Food Interaction

None (not applicable for topical use).

Alcohol Interaction

Safe

Special Populations

Pregnancy

Caution

Children

Not approved for children under 12 years

Elderly

Standard adult dosing; monitor for skin sensitivity

Kidney Impairment

No adjustment needed

Liver Impairment

No adjustment needed

Storage & Patient Advice

Stopping the Medicine

Discontinue if no improvement after ~2 months; stop immediately if significant irritation or ochronosis occurs; tapering is not required

Overdose

Topical overuse may cause marked local irritation (erythema, burning, peeling); systemic toxicity from topical use is unlikely; if ingested, seek urgent medical/poison-center advice

Patient Counseling

Apply a thin layer to hyperpigmented areas only (avoid normal surrounding skin) typically twice daily unless prescriber directs otherwise; avoid eyes/mucosa and broken/irritated skin; use daily broad‑spectrum sunscreen (preferably SPF ≥30) and minimize sun exposure; consider patch test initially; expect improvement in ~4-8 weeks; do not use continuously beyond ~2-3 months without medical review; stop and seek care if severe irritation, blistering, or blue‑black darkening (exogenous ochronosis) occurs; prescription medicine-do not share.

Monitoring Requirements

No routine labs required; monitor clinically for irritation/contact dermatitis and for rare paradoxical darkening/exogenous ochronosis, and reassess response by ~2 months.

Pharmacology

Mechanism of Action

Reversible depigmentation primarily by inhibiting tyrosinase (blocking oxidation steps in melanin synthesis, including conversion of tyrosine to DOPA), reducing melanin production in melanocytes.

Onset of Action

Visible lightening typically begins in about 4-8 weeks (often around 5-7 weeks).

Duration of Effect

Benefits are maintained only with ongoing photoprotection and/or maintenance therapy; hyperpigmentation commonly recurs after discontinuation, and persistence varies (not reliably 2-6 months).

Half-Life

Unknown/not well established for topical hydroquinone (systemic half‑life is not routinely characterized for topical use).

Bioavailability

Approximately 35%-45% systemic absorption can occur after topical application (variable with skin integrity, area, and occlusion).

Excretion

Primarily renal (urinary) excretion as water‑soluble conjugated metabolites (e.g., glucuronide/sulfate).

Product Information

Available Dosage Forms

Cream (this product: 4% topical cream).

Composition per Dose

Each 1g of cream contains: 40mg Hydroquinone.

Generic Availability

Yes

OTC Alternatives

Non‑hydroquinone OTC depigmenting options such as azelaic acid, kojic acid, vitamin C (ascorbic acid), niacinamide, alpha‑arbutin, glycolic acid/AHAs, and (where available OTC) topical tranexamic acid; note: hydroquinone 4% is prescription (and hydroquinone 2% OTC status varies by country and is not reliably OTC).

Skin Condition

Hyperpigmentation

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.